Reduced Annexin A3 in schizophrenia

Area of Science:

• Neuroscience
• Psychiatry
• Molecular Biology

Background:

• Schizophrenia's underlying cellular and molecular mechanisms remain unclear, with growing interest in neuroplasticity and inflammation.
• Annexins, including Annexin A3 (ANXA3), are implicated in inflammation and membrane metabolism, potentially linking to schizophrenia pathogenesis.

Purpose of the Study:

• To investigate Annexin A3 (ANXA3) protein levels in first-episode, drug-naive patients diagnosed with schizophrenia and bipolar disorder.
• To compare ANXA3 levels in patient groups against age- and gender-matched healthy controls.

Main Methods:

• Western blot analysis was employed to quantify protein expression of Annexin A3 (ANXA3).
• Platelets were used as the biological sample source from 28 schizophrenia patients, 27 bipolar disorder patients, and 30 healthy controls.
• All patient diagnoses adhered to DSM-IV criteria, and participants were drug-naive and experiencing their first psychotic episode.

Main Results:

• Annexin A3 (ANXA3) levels were significantly reduced in schizophrenia patients compared to both healthy controls (p < 0.001) and bipolar disorder patients (p < 0.001).
• Undetectable Annexin A3 (ANXA3) levels were observed in 20 out of 28 schizophrenia patients, whereas none were detected in bipolar disorder patients or controls.
• A marked reduction in ANXA3 was evident in drug-naive schizophrenia patients.

Conclusions:

• Reduced Annexin A3 (ANXA3) levels are associated with first-episode, drug-naive schizophrenia.
• ANXA3's known roles in neuroplasticity, inflammation, apoptosis, and membrane phospholipid metabolism suggest its potential involvement in schizophrenia.
• Further research with larger cohorts is recommended to explore the potential of reduced ANXA3 as a schizophrenia risk marker.